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Background: Recent technical advances in digital image capture and analysis greatly improve the measurement of
protein expression in tissues. Breast cancer biomarkers provide a unique opportunity to utilize digital image analysis
to evaluate sources of variability that are caused by the tissue preparation, in particular the decalcification treatment
associated with the analysis of bone metastatic breast cancer, and to develop methods for comparison of digital
data and categorical scores rendered by pathologists.
Methods: Tissues were prospectively decalcified for up to 24 hours and stained by immunohistochemistry (IHC)
for ER, PR, Ki-67 and p53. HER2 positive breast cancer sections were retrieved from the pathology archives, and
annotated with the categorical HER2 expression scores from the pathology reports. Digital images were captured
with Leica and Aperio slide scanners. The conversion of the digital to categorical scores was accomplished with a
Gaussian mixture model and tested for accuracy by comparison to clinical scores.
Results: We observe significant effects of the decalcification treatment on common breast cancer biomarkers that
are used in the clinic. ER, PR and p53 staining intensities decreased 15 – 20%, whereas Ki-67 decreased > 90%
during the first 6 hrs of treatment and stabilized thereafter. In comparison with the Aperio images, pixel intensities
generated by the Leica system are lower. A novel statistical model for conversion of digital to categorical scores
provides a systematic approach for conversion of nuclear and membrane stains and demonstrated a high
concordance with clinical scores.
Conclusion: Digital image analysis greatly improves the quantification of protein expression in human tissues.
Decalcification affects the accuracy of immunohistochemical staining results and cannot be reversed by image
analysis. Measurement data obtained on a continuous scoring scale can be converted to categorical scores for
comparison with categorical dataset that are generated by pathologists.
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Digital image analysis is used increasingly to quantify pro-
tein expression in human tissues. A computer-assisted
approach has advantages compared to the conventional,
visual assessment of staining intensities in terms of quan-
tification, dynamic range, reproducibility and sensitivity
[1,2]. However, like any method it is affected by technical
variability that is incompletely understood. Here we sys-
tematically examine sources of technical error that ori-
ginate from the imaging system and tissue preparation.
We also demonstrate a statistical approach to convert the
staining intensity that is measured by the instrument into
a categorical score that is familiar to pathologists and
researchers reporting protein expression in tissues.
Immunohistochemistry (IHC) has advantages and dis-
advantages over fluorescent detection of protein expres-
sion. IHC generates a permanent staining record, depicts
the tissue architecture for accurate diagnosis and per-
mits amplification of the signal using a number of post-
amplification reagents (polymers and tyramide) [3,4].
However, the disadvantages of IHC are its lack of linear
signal amplification, the difficulties to utilize multiple
antibodies simultaneously and the imprecision of colori-
metric measurements. Further disadvantages include the
intra- and inter-observer inconsistencies of reporting
staining intensities. Therefore, there is a need to seek
computer assistance to improve the accuracy and repro-
ducibility of IHC- based measurements and to establish
a systematic approach for converting digital into visual,
categorical scales that are used by pathologists.
There are multiple systems available for generation of
digital images and for their analyses. The Leica SCN400
and Aperio ScanScope AT Turbo instruments (Leica
Biosystems, Buffalo Grove, IL) generate high-resolution
whole slide images at a rapid rate and according to man-
ufacturers’ label both devices provide image quality that
is suitable for diagnostic pathology and pathology re-
search. Since digital images may slightly differ from dir-
ect visualization of slides through the light microscope,
pathologists dictate the ultimate acceptance and uti-
lization of the slide scanning instruments in clinical prac-
tice, education and research.
There are human weaknesses in the visual assessment of
stained slides that can be overcome by analytical software.
Pathologists train for many years in pattern recognition
and no single software package today parallels the diag-
nostic skills that acquired through this training. While hu-
man observers poorly distinguish shades of coloration at
low staining intensities or estimate percentages of regions
with specific features (low versus high staining intensities,
or different grades) [5], machine vision techniques can
overcome these weaknesses. The computer-assisted rep-
roducibility of immunohistochemical scoring constitutes
a critical factor in the development of biomarkers forclinical applications. There exist several commercial [6-8]
and open source software packages [9-12] to quantify
breast cancer biomarkers by image analysis. Existing sys-
tems can measure the immunoreaction product (brown
diaminobenzidine (DAB) precipitate) that correlates with
the abundance of the HER2/ErbB2 protein and discrim-
inate between cells that are negative, weak and dark in
terms of brown color. The FDA recently approved soft-
ware that is incorporated into the Aperio slide scanner.
The software contains an algorithm to covert digital
to categorical scores of HER2 expression in breast can-
cer [8] and demonstrates that changing continuous
to categorical formats of immunohistochemical data is
feasible.
Utilizing a commercial system for IHC analyses (Leica
Biosystems Buffalo Grove, IL) we quantified the effect of
the tissue preparation on the measurement of biomarkers
that are used in the clinic for prognosis and treatment of
patients with breast cancer. We probed the effects of a
tissue decalcification agent on nuclear expressions of ER,
PR, p53 and Ki-67. Optical properties of the Leica system
were qualitatively compared to an FDA cleared hardware-
software system Aperio (Leica Biosystems, Buffalo Grove,
IL). We also applied a statistical model to covert digital
DAB intensity scores to categorical scores. The combined
approach for quantification of nuclear and membranous
immunostains should allow for an easier adaptation and
a more common utilization of digital pathology platforms
for biomarker development.
Methods
Tissue and decalcification process
Cancer tissues from 9 serial breast cancer cases with a
large tumor volume were collected prospectively. The
tissue samples were obtained from the excess that was
left over after sections were submitted for routine patho-
logic evaluation. The analyses of immunohistochemal
markers in these cases was considered exempt by the
Cedars-Sinai Medical Center’s Institutional Review Board
(IRB) (not subject research), since the research only in-
cluded remnant tissues and medical records were not
accessed. The only information collected from pathology
reports was the tumor stage. The data were attached to
the specimen immediately when the report became avail-
able and the connection to the report permanently
destroyed right away, rendering future case identification
impossible. Tumor samples were fixed in 10% neutral
buffered formalin for longer than 6 hours, but less than
48 hours as per College of American Pathologist’s guide-
lines [13-15]. Subsequently, 2.5 × 2.0 × 0.3 cm tissue
pieces were placed in cassettes, washed in water and dec-
alcified using a hydrochloric acid-based decalcification
solution (Decal State, Decal Chemical Corp., Tallman,
NY). The decalcification times were 0, 1, 6 or 24 hours.
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and stored in 70% ethanol until processing.
Leica PELORIS premium tissue processor (Leica
Biosystems, Buffalo Grove, IL) was used for tissue pro-
cessing, that involved: 10% neutral buffered formalin for
20 min at 45°C; 70% ethyl alcohol for 20 min at 45°C;
90% ethyl alcohol for 20 min at 45°C; 100% ethyl alcohol
for 20 min at 45°C; 100% ethyl alcohol for 20 min at
45°C; 100% ethyl alcohol for 20 min at 45°C; 100% ethyl
alcohol for 20 min at 45°C; xylene for 30 min at 45°C;
xylene for 30 min at 45°C; xylene for 60 min at 45°C;
paraffin wax for 40 min at 65°C; paraffin wax for 40 min
at 65°C; paraffin wax for 60 min at 65°C [16].
Immunohistochemistry
Immunohistochemical staining with antibodies (all predi-
luted and purchased from Ventana Medical Systems, Tuc-
son, AZ) for estrogen receptor (ER, mouse monoclonal
clone SP1), progesterone receptor (PR, mouse monoclonal
clone 1E2) human epidermal growth factor receptor-2
(HER2, rabbit monoclonal clone 4B5), cell proliferation
marker Ki-67 (rabbit monoclonal clone 30–9), and p53
protein (mouse monoclonal clone D07) were performed
on 4-μm thick tissue sections on the Ventana autostainer
(Ventana Medical Systems, Tucson, AZ). Reagents and
conditions, such as antigen retrieval and antibody incuba-
tions were all predefined by Ventana [17]. Bound second-
ary antibodies were visualized with 3,3-diaminobenzidine
(DAB) chromogen substrate. After immunostaining, the
slides were counterstained with haematoxylin.
Cases selection, digital image acquisition,
histopathological evaluation and image annotation
All cases expressed ER, PR and Ki-67. Four cases
expressed p53 and only one case was positive for HER2.
Only cases that were positive before decalcification treat-
ment were selected for image analysis. To obtain an
adequate cohort of HER2 positive cases, slides were re-
trieved from the pathology archives under an IRB ap-
proved protocol. These HER2+ cases were annotated
with HER2 scores from the pathology report: 3 cases
with HER2 = 0, 4 cases with HER2 = 1+, 4 cases with
HER2 = 2+, and 4 cases with HER2 = 3+. A representa-
tive slide was selected by a pathologist (SM) for image
analysis. 480 digital images were captured at × 20 magni-
fication from 95 slides on the Leica SCN400 whole slide
scanner (Additional file 1: Table S1). All images were
saved as 24bit RGB color images in (*.svs) Leica
platform-specific format and stored on a Digital Image
Hub (DIH) (Leica Biosystems, Buffalo Grove, IL) for
quantification. Using a self fabricated image annotation
tool, a pathologist outlined up to 5 randomly selected
tumor regions with approximately 2000 cells on each
image for quantification (Additional file 1: Table S1).Qualitative evaluation of image capture in Leica and
Aperio instruments
Before testing the accuracy of the conversion, we evalu-
ated the effects of the instrumentation on the staining
intensity (Additional file 2). To compare the basic image
capture properties of the Leica SCN400 scanner and the
Aperio ScanScope AT Turbo, one HER2+ and one ER +
slide were randomly selected and digitized at 20 ×mag-
nification on both instruments. The normalized histo-
grams from identical rectangular tissue regions in the
three basic color channels were extracted for compari-
son. Monochromatic images of the same tissue area (one
from SCN400 scanner, and one from Aperio ScanScope
AT Turbo) were co-registered to measure local intensity
correspondence. A graph showing correlation of output
intensities was also formed.
Image analysis and statistical evaluation
The Leica Tissue IA software package [18] was used for
analysis. First, DAB images were deconvoluted [19] and
then thresholded at t0 level light transmission to remove
background and negative (with no DAB staining) pixels.
t0 was set using a global histogram thresholding method
[20]. For tissue images with nuclear ER, PR, p53 and Ki-
67 staining, a nuclear segmentation procedure returned
a nuclear mask for analysis. If the average DAB signal
was above t0, the nucleus was considered negative.
Otherwise it was positive. The percentage of Ki-67 posi-
tive nuclei was reported with its mean and standard de-
viation. For ER, PR and p53 stain, the average staining
intensity in a delineated region was calculated. The aver-
age intensities at different decalcification times were
normalized to the zero time point and plotted as a per-
centage of staining prior to decalcification. To evaluate
differences between any two time points, distributions of
the average intensities and percentages of positive cells
were compared across all times for each marker. The
distributions were approximately normal at each time
except p53, and thus differences in means across the
times were assessed by 1-way analysis of variance
(ANOVA) models. For each ANOVA model, the signifi-
cance was confirmed by Welch’s ANOVA on the ranks.
Following a significant model, pairwise time compari-
sons were made using Tukey studentized range tests,
which control the type 1 error rate. For p53 the Kruskal-
Wallis test was used rather than ANOVA and pairwise
time comparisons were made using the Wilcoxon rank
sum test, with a Bonferroni-adjusted significance level of
0.05/6 = 0.0083 to evaluate differences between any two
time points.
Conversion of linear to categorical scoring
Four digitized ER + slides and four HER2+ slides graded
as 0, 1+, 2+ and 3+ were selected. From each slide a
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taining approximately 10,000 cancer cells with heteroge-
neous staining was selected, subjected to DAB color
deconvolution and thresholding (described above). The
intensity values of positively stained cells were collected
and modeled as a mixture of Gaussian components.
Since the clinical HER2 grading involves three categories
(weak, moderate and strong staining), we fit a model of
three Gaussian components and applied the Expectation-
Maximization (EM) algorithm to model the three prob-
ability density functions. Each category was assumed to
have a normal distribution, which was defined by a mean
and a standard deviation N (μ, σ). μ and σ were deter-
mined by the expectation–maximization (EM) algorithm
as those of maximum likelihood in the Gaussian mixture
model. Initialization of EM was performed by the k-
means algorithm. The mean and standard deviation
(μ1–3, σ1–3) was calculated for each FOV and used to de-
rive the Gaussian distributions. The thresholds (t1 and t2)
for the staining categories are at the 2 points of intersec-
tion of the Gaussian distributions and were projected
onto an intensity axis (abscissa) to define thresholds of
DAB intensity categories. The derived ER and HER2
thresholds were applied to all images in the study and the
fractions (range 0 – 1) of stained cells categories: weak,
moderate and strongly were determined in each FOV.
Fractions were multiplied by the category rank, providing
values between 0 and 3. These values from HER2 stained
slides were compared against pathologist grading and
Aperio scoring.
Results
Bone is a common site of metastatic breast cancer. In
order to treat patients with bone metastasis, ER, PR and
HER2 receptor status play important roles in treatment
decisions and drug selections. Since bone biopsies are
decalcified prior to immunohistochemical staining to
prepare the bone for the generation of micro thin sec-
tions, the validity of biomarker measurements is endan-
gered by the decalcification treatment. Here we utilize
image analysis to determine the effects of decalcification,
evaluate the measurement error that is caused by the in-
strumentation and develop a statistical approach to con-
vert digital into categorical scores, which are routinely
used by pathologists to communicate the immunohis-
tochmical results to oncologists.
Effects of decalcification on the quantification of nuclear
breast cancer biomarkers in tissues
The advantages of a computer assisted approach over
visual assessment in the quantification of immunohis-
tochemistry are the consistency of the measurement,
which eliminates intra-observer and inter-observer vari-
ability, the improved accuracy, in particular in the lowintensity range and the accuracy in the enumeration of
percentages of nuclear or cell surface signals. A typical
workflow for quantification of nuclear or membranous
protein expression in slides stained with DAB involves
the following steps: (a) numerical separation of the DAB
image from the haematoxylin image, (b) segmentation of
nuclei based on the haematoxylin image or of cell mem-
branes based on the DAB image, (c) determination of
thresholds to quantify the percentage of cells with differ-
ent levels of DAB positivity, and (d) enumeration of cells
within levels of signal intensities defined according to (c).
To determine the effects of the decalcification time,
tissue images were analyzed with image analysis software
(Leica Tissue IA, Leica Microsystems, Buffalo Grove, IL)
[18]. A progressive decline of staining intensity with
time of decalcification was observed for all markers. The
average loss for p53 was 20%, while ER and PR staining
was reduced by 15% (Figure 1A-C). A significant decline
(p < 0.005) occurred after the first hour of treatment.
Longer treatment times of 6 and 24 hours did not cause
further losses, demonstrated by insignificant differences
in staining intensities between the 6 and 24 hours time
points (p > 0.05). The greatest effect of the decalcifica-
tion treatment was observed for Ki-67 immunoreactivity,
which reports cell proliferation. Ki-67 staining decreased
from an average of 35% to below the limit of detection
after decalcification for 1 hr (p < 0.005) (Figure 1D).
To determine the heterogeneity of expression of
each protein within the cancer, we calculated the % CV
across the 5 areas that we measured in each slide. The
intra-tumor heterogeneity ranged between 0.2 and 11%
(Figure 1E). In no case did decalcification increase the
staining intensity.
Overall, the effects of decalcification were significantly
greater for Ki-67 than for ER, PR and p53. The decrease
in staining intensity occurred rapidly, with a significant
drop after treatment for 1 hour and stabilized between 6
and 24 hours of treatment.
Conversion of linear staining intensity to categorical
scoring
While ER, PR and Ki-67 are quantified routinely by
image analysis during the clinical workup of breast can-
cers and are reported as the percentage of positive cells
in the clinical pathology report, the clinical assessment
of HER2 expression is based on a categorical 0, 1+, 2+
and 3+ scale. In general, pathologists use categorical
scores to compare IHC staining intensities across cases
and categorical scores are also used in most research
projects that are designed to assess the role of IHC
markers in diagnostic questions and in therapy and dis-
ease outcomes prediction. In order to compare studies
that utilize image analysis to studies published by pa-
thologists, the digital score of the computer image must
Figure 1 Quantification of breast cancer biomarkers in tissues treated by decalcification: The study involved 9 cases and 5 fields per
slide were measured at each time point. A - C) The average staining intensities at each time point across all slides are plotted on the Y-axis
for the estrogen receptor (A), progesterone receptor (B) and p53 (C) and the % Ki-67 positive cells are platted in D. The X-axis indicates the time
interval of the decalcification treatment. *p < 0.005 versus baseline. E) The %CV across 5 fields in each slide is shown for 29 slides stained for ER,
20 stained for PR, 12 stained for p53 and 18 stained for Ki-67.
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the methodology to accomplish this conversion in a
standardized fashion is not available.
To develop a conversion approach from digital to cat-
egorical scoring, approximately 10000 cells in multiple
tumor areas with heterogeneous staining were extracted
from 4 digitized slides stained either for HER2 or ER.
Fields of view, FOVHER2 and FOVER, were deconvoluted
into separate images for DAB and hematoxylin. A
threshold to eliminate the background was set at the
level of t0 = 230. Pixel intensities lower than t0, which
are indicative of positive staining were statistically mod-
eled by the Gaussian mixture model and classified as
strong, moderate or weak. The output of the model is
shown in Figure 2 and consists of 3 distributions that
intersect at t1 and t2, which represent the thresholds that
separate strong from moderate, and moderate from weak
staining categories. These thresholds are subsequently
applied to categorize staining intensities of nuclei or cell
membranes in the entire cohort. For HER2 immunohis-
tochemical stains, the algorithm separated strong staining
(3+) with values between 0 and 85, moderate staining
(2+) with values from 86 to 180 and weak staining (0, 1+)
181 to 230 (Figure 2). For ER staining, cutoffs were < 83
for strong staining (3+), < 169 for moderate (2+) and
between 170 and 230 for weak (0, 1+) staining.
Before testing the accuracy of the conversion, we eval-
uated the effects of the instrumentation on the staining
intensity. Slides that were stained with the HER2 or ER
antibodies were scanned on the Aperio and Leica slide
scanners. Image intensity range 0–255 was divided into
three zones: strong, moderate, weak and negative with
background determined by thresholds from Figure 2A,Figure 2 Conversion of linear to categorical scoring. The intensity histo
modeled using the Gaussian mixture. The Expectation-Maximization (EM) a
means and standard deviations for strong, moderate and weak intensity ra
corresponding to less coloration. The probability density (Y axis) represents
230 white pixel intensity in DABHER2 and DABER images. Pixel intensities ind
1+/0 respectively.and areas under the histogram (Additional file 3: Figure
S1A and B) for each zone in red, blue, green and mo-
nochromatic channels zone were calculated (Additional
file 1: Table S2). A comparison revealed larger areas
under the curve that corresponded to pixel numbers in
weak, moderate and strong staining intensity categories
in the image that was acquired with the Leica scanner.
On the contrary, Aperio image had substantially greater
areas in the negative and background pixel ranges, indi-
cating a rightward shift of the Aperio RGB histograms.
In addition, at all white pixel intensities, greater white
pixel numbers indicative of lesser color pixels were
measured with the Aperio instrument for both HER2
and ER IHC stains (Additional file 3: Figure S1C and D).
Altogether, these data demonstrate that the images cap-
tured with the Leica instrument are darker, compared to
those from the Aperio instrument.
To test the accuracy of the conversion approach from
digital to categorical scoring, we used clinical cases of
HER2 positive and negative breast cancers from the
pathology archives (n = 15). Breast cancer cases routinely
undergo assessment for HER2 expression by pathologists
and expression levels are communicated in the pathology
report using a categorical scale of 0, 1+, 2+ and 3+. To
compare the results obtained by our approach to the
pathologist we calculated the average categorical score
from image analysis results. Cancer cells in an area
were assigned to weak, moderate or strong categories
(Figure 3A) and the fraction of cells in each category (in
a range of 0 to 1) was multiplied with the intensity score
(1 – 3) to derive the average score of the image. As
shown in Figure 3A cases clustered according to the
assigned clinical grades. In addition, cases in each of thegram (panels inside A and B) obtained from a whole slide image was
lgorithm was applied to model three Gaussian components with the
nges. The white pixel intensity is plotted on the X axis with high values
the frequency of pixels. A background cutoff was chosen arbitrarily at
icated by thresholds t1 and t2 separate 3+ from 2+ or 2+ from
Figure 3 Visualization of staining categories of Her2 membrane expression. A) Each point represents one region from a slide. Data of
weak, moderate and strong positive cells and of negative cells were collected. Three categories (1, 2 and 3) of positive cells were defined based
on t1 and t2 thresholds in Figure 2. The percentages of cells in weak, moderate and strong staining categories are plotted on X, Y and Z axes.
Note clusters of HER2 grade 0 and 1+ (green and red dots), HER2 grade 2+ (black) and 3+ (pink). B) Relationship between staining score
(mean +/− std) and clinical HER2 expression. Staining scores were calculated by summing up the percentages of cells multiplied by 1, 2 and 3.
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range that was not overlapping with the other groups,
suggesting that the separation between intensity cat-
egories can be unequivocally accomplished (Figure 3B).
Discussion
In clinical pathology practice, breast cancer biomarkers
are used irrespective of the origin of the tissue and the
process of sample preparation. Breast cancer frequently
metastasizes to the bone. To examine bone biopsies, the
tissue needs to be softened through decalcification. Im-
munohistochemistry for ER and PR is most commonly
used to strengthen the diagnosis of breast cancer in
bone biopsies. In addition, Ki-67 and p53 are used occa-
sionally for prognostication and treatment guidance. The
possibility that the decalcification process changes the
intensity of the biomarker signals has not been ad-
dressed systematically. Therefore in this study, we exam-
ine the effects of the decalcification process on common
breast cancer biomarkers. In order to determine the time
dependence of the decalcification treatment, we use tis-
sues form breast surgeries. We reasoned that decalci-
fication effects will be similar in primary and bone
metastatic cancer and that utilizing breast cancer in sur-
gical resection provides an adequate starting point to
test the consequences of decalcification on breast cancer
biomarkers. To exclude the unlikely possibility that the
presence of bone might influence the results, we added
bone spicules to the decalcification treatment, but did
not observe a change in IHC results (data not shown).
For all 4 markers, the signal decreased for up to
6 hours of treatment and then stabilized. It is encour-
aging that longer decalcification times (>6 hours), which
are needed to soften the bone for the preparation of
slides, do not cause excessive destruction of protein ana-
lytes. Since ER and PR are used to confirm a breastcancer diagnosis, the small decline in the signal (~15 -
20%) does not reduce the diagnostic utility. On the other
hand, the massive loss of Ki-67 staining to the point
where the signal is no longer detectable discourages the
use of Ki-67 to assess cell proliferation in decalcified tis-
sues, not only for breast cancer, but also for other cancer
types in the bone.
Another study also reports a reduction in staining for
Ki-67 after tissue decalcification. The European Bone
Marrow Working Group assessed the effects of fixatives
and decalcification protocols on immunohistochemical
analysis of bone marrow biopsies. Amongst 6 markers
that are routinely used in the workup of bone marrow
biopsies for hematologic malignancies, Ki-67 and CD117
were the most problematic across the 19 hospitals that
participated in the study [21]. Surprisingly, ER staining
was less affected by the decalcification process than Ki-
67, despite being characteristically sensitive to tissue
photo-oxidation [22]. In addition to decalcification and
photo-oxidation, the loss of immunoreactivity through
slide storage is another worrisome possibility and re-
ported to be more severe for PR and HER2 compared to
ER [23]. Thus in addition to the breast cancer biomarker
used in this study, each IHC marker needs be evaluated
individually tested for its sensitivity to various pre-
analytical conditions that might affect the accuracy of its
measurement.
The measurement of protein expression by digital
image analysis is advantageous, because it is more accur-
ate, reproducible and sensitive at low staining intensities
[5,7,8]. Several instruments are available for the acquisi-
tion of digital images, however comparing acquisition
parameters between instruments is usually not possible,
because investigators normally only have access to one
instrument. We took advantage of the available Leica
and Aperio instruments at our institution to compare
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generate high quality digital images, however, the Leica
images are darker. The Leica instrument captures a lar-
ger number of color pixels in all 3 RGB channels and
the numbers of white pixels are proportionally smaller.
The correlation coefficient for the white pixel intensities
comparing Leica and Aperio is >0.9 and the systematic
error was consistent across pixel intensities (Additional
file 3: Figure S1C and D). The observed differences in
images captured by Leica and Aperio instruments may
arise from differences in the optics and in the power of
the light source, which affect the amplitude, position and
width of the color components. A halogen bulb is used in
the Aperio ScanScope AT Turbo, while a semiconductor-
based light emitting diode device is used as the light
source in the Leica SCN400 instrument [personal com-
munication with Leica]. Images from the Aperio possess
fewer blue pixels than those from the Leica instrument.
Hence, the cell membranes in Leica images appear darker
and the nuclear structure is finer. The closer proximity of
histogram peaks in Aperio images to the limit of detec-
tion results in an overall weaker appearing stained slide.
In addition the red histogram in the Leica image is
shifted towards the high intensity range to a greater
extent than the other color components, generating a
“warmer” image. However, these results will unlikely
affect study outcomes or conversion from digital to cat-
egorical scores.
Because of the superior performance of digital image
analysis versus a human observer, the utilization of com-
puter assisted image analysis is on the rise. However, the
lack of a universal method to convert digital into cat-
egorical scores hinders the validation of digital image
analysis by comparison with traditional image analysis
systems. There are only a few examples of digital to cat-
egorical conversion methods. A conversion method was
reported to classify pancreatic islets in diabetic rates as
either normal or abnormal. The investigators employed
a finite mixture mathematical model, which is similar to
our algorithm and includes seven islet parameters from
digital image analysis. The model possessed high accur-
acy for dividing islets into normal and abnormal cate-
gories [24]. Another example in the clinical molecular
pathology laboratory is the conversion of digital to cat-
egorical scores that is included in the FDA approved
analysis software of the Aperio slide scanner [25]. The
software is limited to analysis of HER2 membrane stain-
ing and it is unclear whether it can be used for measure-
ments other than HER2 stained slides. A weakness of
these approaches, including our approach is the com-
parison of a pseudo-scientific categorical grading system,
which has been clinically validated with a quantitative
and more precise digital scale. A better method for com-
parison would be the analysis of samples by westernblotting or molecular biology. However, this is not feas-
ible for formalin fixed samples in this study.
To fill the need for more open source digital-to-
categorical conversion systems for a broad range of
applications, we developed an approach that is not re-
stricted by the localization of the immunohistochemical
signal. Our approach, which models strong, moderate
and weak intensity intervals by fitting a Gaussian distri-
bution curve within each intensity window, can be ap-
plied universally to IHC stained slides. The cutoffs for
weak, moderate and strong staining are established with
4 images that span the entire immunohistochemical in-
tensity spectrum of the project. The settings of cutoffs
are statistically derived, independent of the observer, and
require only a small set of training data. When the cutoffs
were applied to a set of 87 regions from 15 HER2 slides,
we calculated categorical scores that corresponded to
those provided by the algorithm of the Aperio instru-
ment. We would also like to point out that our amalgam-
ated algorithm for conversion of linear to categorical
scoring differs from that included in the Aperio software
package which quantifies cells by membrane staining
intensity and completeness. Although our solution is
devoid of the latter constituent, it can still provide
meaningful results.
Thus, by applying the algorithm we developed to con-
vert digital to categorical scores, we can accomplish a
valid comparison of digital and categorical datasets for
IHC-stained slides for both membranous and nuclear
markers.
Conclusions
In summary, we use digital image analysis to accurately
determine the effects of tissue decalcification on bio-
markers that are in clinical use for the diagnosis and treat-
ment of breast cancer. Our novel statistical method to
generate data from digital images that can be compared to
pathologists’ assessment of immunohistochemical stains
provides the means for a standardized approach and a
tool to compare digital data to those generated by
pathologists.
Additional files
Additional file 1: Table S1. Slide and region of interest numbers in the
study. Regions of interests were outlined by a pathologist. Each region
contained on average 2000 cells. Table S2. Normalized areas under the
curve for image histograms acquired by Aperio and Leica instruments.
Additional file 2: Methods.
Additional file 3: Figure S1. Comparison of image capture properties
between Leica and Aperio instruments. The same slide was imaged using
Leica SCN400 and Aperio ScanScopeAT Turbo instruments. Panels A and
B depict intensity histograms extracted from digital images obtained with
Aperio and Leica respectively. Color lines indicate intensities in the red,
green and blue channels as well as their grayscale transformation (black
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http://www.diagnosticpathology.org/content/9/1/213line). Inserts provide examples of slide contents from breast cancer
samples stained with the HER2 antibody. Discrepancies in coloration in
the immunohistochemistry images correspond to the differences in
histogram shapes of all three channels. C) Relationships between white
pixels acquired by Aperio and Leica slide scanners for a slide stained with
HER2 antibody. The membrane staining was evaluated in the range of
white pixels from 120 to 240 (See methods section). D) Same as C) but
for a slide stained with ER antibody. A linear regression model was used
to fit the data. Figure S2. Distribution of cells from all slides within three
categories of HER2 staining intensity. Three staining categories were
defined based on thresholds (t1 and t2) shown in Figure 1. Each slide
received a pathological score of HER2 expression of 0, 1, 2 or 3. HER2
staining was quantified in five regions and the staining score was
assigned to one of the three staining categories. Panel A shows the
distribution of cells with negative or weak positivity in slides that were
graded between 0 and 3 by a pathologist. Panel B, and C show the
distribution of cells with moderate and strong positivity respectively. In
total 87 regions from 15 slides were analyzed.
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